The Evolution To Treatment Of Hypertension With Advanced Formulation
|
|
- Zoe Hopkins
- 5 years ago
- Views:
Transcription
1 The Evolution To Treatment Of Hypertension With Advanced Formulation Dr. Donald Ang MBChB (UK) FRCP (Edin) MD (UK) CCST Cardiology (UK) FESC (Europe) Consultant Cardiologist Island Hospital Penang
2 High Blood Pressure, High Blood Cholesterol and CV Diseases CVD Burden Systolic blood pressure over 115 mm Hg 50% Blood Pressure Cholesterol Overall, 61% of cardiovascular disease is due to high blood pressure and/or cholesterol WHO Global Programme on Evidence for Health Policy
3 Major Public Health Issue: The rate of Hypertension is Increasing 26.4% In 2000, > quarter of the global population had hypertension Population (in millions) with hypertension globally 1,2 Predicted increase 60% Yr 1980 Yr 2000 Yr 2008 Yr Kearney et al. Lancet 2005;365: WHO Global Atlas on Cardiovascular Disease Prevention and Control 3
4 Stroke and Ischemic Heart Disease Mortality Linked to SBP Levels Stroke Ischemic Heart Disease Lewington et al. Lancet 2002;360:
5 Even Small Increases in BP Increases Risk for CVD Each 2 mmhg rise in mean SBP 7% 10% Risk of mortality from ischemic heart disease Risk of mortality from stroke Therefore, reducing BP prevents CV outcomes in patients with hypertension National Institute for Health and Clinical Excellence (NICE). Hypertension Clinical Guideline 127:
6 Increased 24-hour BPV has been associated with CV risk Incidence of mortality and cardiovascular events by fifths of the distributions of the systolic average real variability in 8,938 patients Hansen TW, et al. Hypertension 2010;55: BPV, blood pressure variability; CV, cardiovascular; NCV, non CV.
7 Different types of BPV, their determinants, and prognostic relevance Pronounced fluctuations in BP can occur over short- and long-term observation periods Parati G, et al. Nat Rev Cardiol 2013;10: AHT, antihypertensive treatment; BP, blood pressure; BPV, BP variability; egfr, estimated glomerular filtration rate.
8 Guidelines on BPV NICE Variability in SBP when measured visit-to-visit is a strong predictor of stroke, independent of mean SBP Whatever the underlying mechanisms, SBP variability appears to be an important independent predictor of clinical outcomes Updated guidance recommends the best available evidence-based treatment options to suppress BPV in people with hypertension ESC/ESH guidelines Consideration should be given to the evidence that visit-to-visit BPV may be a determinant of CV risk, independently of the mean BP levels achieved during long-term treatment, and that, thus, CV protection may be greater in patients with consistent BP control throughout visits The target for management of hypertension should be BPV control BP, blood pressure; CV, cardiovascular; BPV, BP variability; SBP, systolic BP. 1. National Institute for Health and Clinical Excellence (NICE) Clinical Guideline 127. Available at: 2. Mancia G, et al. Eur Heart J 2013;34:
9 Association between CV events and early morning period 18:00 0:00 6:00 12:00 Time of day 1. Muller JE, et al. N Engl J Med 1985;313: Marler JR, et al. Stroke 1989;20: CV, cardiovascular risk; EMBPS, early morning blood pressure surge.
10 Pooled increase in coefficient of variation (%) Pooled variance ratio CCBs reduce systolic BPV more than other antihypertensive agents: Meta-analysis data 1.50 In a meta-analysis of 389 clinical trials, group systolic BPV was significantly reduced following treatment with CCBs Pooled VR = 0.89; 95% CI, ; P = There was an increase in group systolic BPV with most other drug classes CCB CCBND DD ARB ACEI BB AB Placebo Treatment allocation AB, alpha-1 blocker; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BB, beta-blocker; BPV, blood pressure variability; CCB, calcium channel blocker; CCBND, non-dihydropyridine CCB; CI, confidence interval; DD, non-loop diuretic drugs. Webb AJ, et al. Lancet 2010;375:
11 CCBs reduce inter-individual systolic BPV more than most other antihypertensives Antihypertensive Class Meta-analysis of 389 trials Effect of Treatment on Inter-individual Systolic BPV Agent class versus all other antihypertensive agent classes Variance Ratio (95% CI) P-value CCB 0.81 ( ) < Non-loop diuretic 0.87 ( ) ACEI 1.08 ( ) ARB 1.16 ( ) BB 1.17 ( ) CCB versus placebo 0.76 ( ) < Webb AJ, et al. Lancet 2010;375: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BB, beta-blocker; BP, blood pressure; BPV, BP variability; CCB, calcium channel blocker; CI, confidence interval.
12 Systolic BPV and risk of stroke lower with CCBs vs other antihypertensives despite similar mean BP Stroke risk Randomized trials with CCBs versus BBs, ACEIs, or ARBs with stroke risk and systolic BPV (SD) reported Events/patients CCB Drug B NORDIL (vs BB/D) 159/ /5471 ASCOT (vs BB) 327/ /9618 VALUE (vs ARB) 281/ /7649 INVEST (vs BB) 176/11, /11,309 ALLHAT (vs ACE) 377/ /9054 CAMELOT (vs ACE) 6/663 8/673 Total 1326/43, /43,774 SBP at follow-up Mean (SD) CCB Drug B Mean SBP difference (95% CI) NORDIL (vs BB/D) (16.3) (17.4) 3.70 (3.07 to 4.33) ASCOT (vs BB) (14.8) (17.8) 1.90 ( 2.36 to 1.44) VALUE (vs ARB) (13.8) (16.2) 1.80 ( 4.92 to 1.32) INVEST (vs BB) (11.0) (10.0) 0.00 ( 0.27 to 0.27) ALLHAT (vs ACE) (15.0) (17.9) 1.30 ( 1.78 to 0.82) CAMELOT (vs ACE) (15.5) (18.0) 0.60 ( 1.20 to 2.40) Total 0.21 ( 0.41 to 0.01) Odds ratio (95% CI) 0.81 (0.66 to 0.01) 0.77 (0.66 to 0.89) 0.87 (0.74 to 1.03) 0.88 (0.72 to 1.08) 0.82 (0.71 to 0.94) 0.76 (0.26 to 2.20) 0.82 (0.76 to 0.88) Variance ratio (95% CI) 0.88 (0.83 to 0.93) 0.69 (0.67 to 0.72) 0.73 (0.68 to 0.77) 0.83 (0.80 to 0.86) 0.70 (0.67 to 0.73) 0.74 (0.64 to 0.86) 0.76 (0.74 to 0.77) ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BB, beta-blocker; BP, blood pressure; BPV, BP variability; CCB, calcium channel blocker; CI, confidence interval; D, diuretic; SBP, systolic BP; SD, standard deviation. Rothwell PM. Lancet 2010;375:
13 Managing white-coat effect and masked hypertension White-coat effect: A discrepancy of more than 20/10 mmhg between clinic and average daytime ambulatory BP monitoring (ABPM) or average home BP monitoring (HBPM) at the time of diagnosis Masked hypertension: The converse of white-coat hypertension. A subject with masked hypertension has normal BP measurements in the office or clinic but may experience episodes of elevated BP outside of the medical environment For people identified as having a white-coat effect or masked hypertension consider daytime ABPM or HBPM as an adjunct to clinic BP measurements to monitor response to treatment National Institute for Health and Clinical Excellence (NICE). Hypertension Clinical Guideline 127: 13
14 2013 European hypertension guidelines: ESH/ESC emphasize out-of-office BP measurement Values Separating from medical environment better reflects true BP condition than office BP Use out-of-office BP for risk stratification: Patients with high office BP but normal out-of-office BP (white-coat hypertension) have lower CV risk than patients with sustained hypertension; the patients with normal office BP but elevated out-of-office BP (masked hypertension) is frequently associated with CV risk factors and has increased risk of CV events Close association with hypertension induced organ damage, especially left ventricular hypertrophy Better prediction of CV morbidity and mortality than office BP Mancia et al. J Hypertens 2013;31:
15 2013 ESH/ESC hypertension guidelines: Self-monitoring of BP is a key component of comprehensive BP management Subject Phenomena Recommended improvements Discontinue Irregular therapy Self-monitoring of BP Self-management by simple patient guidance system Patients Establish patient population Strategic information Comprehensive intervention: Including message, reminder, BP self-monitoring, telephone follow-up, or working environment or pharmacy-based projects Comprehensive BP management focusing on patients and combining doctors and communities Poor compliance is a global problem o One-third of patients will discontinue the initial therapy within 6 months after treatment, and only one half of patients will continue treatment after 1 year o Self-monitoring of BP is an important means of improving adherence Mancia et al. J Hypertension 2013;31:
16 Definitions of hypertension by office and out-of-office blood pressure levels (mmhg) Category Systolic Diastolic Office BP 140 and/or 90 Ambulatory BP Daytime (or awake) 135 and/or 85 Nighttime (or asleep) 120 and/or h 130 and/or 80 Home BP 135 and/or 85 Mancia et al. J Hypertension 2013;31:
17 Out-of-office BP Methodologic aspects ABPM Measurement extended to hours (includes the night) Difference from operator-measured BP to be checked Diary on events potentially influencing BP useful Measurements to be made at same frequency (eg, every 20 min) during day and night Excessive intervals to be avoided Recording satisfactory if 70% of values available HOME BP To be measured on at least 3 4 days (preferably 7 days) Morning/evening values (quiet environment) Values to be reported in standardized logbook but storage in memory equipped device useful Possible advantage of telemonitoring Data interpretation always by physician Mancia et al. J Hypertension 2013;31:
18 HBP telemonitoring improves hypertension control in general practice Adapted from Parati G et al. J Hypertens 2009;27: A sample of 391 patents with uncontrolled hypertension (80% treated) randomized to usual care (office BP) or to integrated care teletransmitted HBP (TELEHBPM) Key Findings o The percentage of daytime BP normalization was higher in the TELEHBPM group (62%) than in control (50%) (P<0.05) o There were less frequent treatment changes in TELEHBPM than in control group (8.7% vs. 13.5%, P<0.05) Parati G et al. J Hypertens 2009;27:
19 The many causes of uncontrolled BP Diverse pathogenesis and etiology RAAS Salt-sensitive, volume of body fluid Sympathetic nerve activity Sleep apnea syndrome Secondary forms Poor adherence with AHTs Reduced self-cv perception Forget Adverse drug reactions Poor therapeutic effects Uncontrolled BP BP types Excessive BP variability Non-dipper/reversed dipper (nighttime) hypertension Morning surge Low renin activity Lifestyle (sodium intake) Interfering substances (eg, NSAIDs) Fail to adjust drug species or dosage timely Improper therapeutic regimens Mancia. J Hypertens 2013;31: White. J Manag Care Pharm 2007;13(suppl S-b):S34-S39 19
20 Patient Compliance is still LOW Adherence rate is only 53.4% in hypertensive patients In other studies looking in to adherence rates to antihypertensive medication, it shows: Only 46% of newly diagnosed patients remain compliant to their medication after 4 years After the first year of medication, there is a drop in compliance in about 50% of the population in the following 2 years.
21 How does compliance affect blood pressure control? Uncontrolled Blood Pressure 50.3% 36.4% Adherers Non adherers Ramli, A. et al. Medication adherence among hypertensive patients of primary health clinics in Malaysia. Patient Preference and Adherence. 2012;6
22 % Non Adherers How number of drugs affect compliance >3 Number of Drugs Taken Ramli, A. et al. Medication adherence among hypertensive patients of primary health clinics in Malaysia. Patient Preference and Adherence. 2012;6
23 % non adherers Compliance remains a problem in all age group especially younger patients Age Group Ramli, A. et al. Medication adherence among hypertensive patients of primary health clinics in Malaysia. Patient Preference and Adherence. 2012;6
24 Cardiovascular Event Rates: Controlled and Uncontrolled Hypertension Kaplan-Meier estimates of cardiovascular event rates in men and women with controlled (<140/90 mmhg) and uncontrolled blood pressure in the Brisighella Heart Study. Adapted from: Borghi C, et al. J Hypertens. 2004;22:
25 Dysphagia Dysphagia varies depending on the disorder1: 29% to 64% - stroke patients 24% to 34% - patients with multiple sclerosis 81% - patients with Parkinson's disease 30% patients with GERD (gastroesophageal reflux) Common complaints in difficulty in swallowing tablets are 2: Size Surface Form Taste of tablets 25 25
26 Oral dispersible tablet (ODT) A solid dosage form containing medicinal substances (or) active ingredient which disintegrates rapidly usually within a matter of seconds when placed upon a tongue (FDA) - United States of America food and drug administration
27 Norvasc ODT Norvasc is the first antihypertensive drug in it s class in Malaysia to have ODT formulation Malaysia is the first country in the SEA region to have launched this formulation. Formulated to increase usability and further enhance medication adherence Once put on the tongue, it disintegrates within seconds Ability to take it without water. The minty taste that Norvasc ODT has will make the medication palatable as well
28 Summary Control of BP remains sub-optimal in many patients Factors that define appropriate BP management/control is more complex than initially understood Roles of home BP monitoring and ABPM in the management of hypertension should be emphasised
Slide notes: References:
1 2 3 Cut-off values for the definition of hypertension are systolic blood pressure (SBP) 135 and/or diastolic blood pressure (DBP) 85 mmhg for home blood pressure monitoring (HBPM) and daytime ambulatory
More informationOutcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension
Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension Prof. Massimo Volpe, MD, FAHA, FESC, Chair of Cardiology, Department of Clinical and Molecular Medicine
More informationIs Traditional Clinic Blood Pressure Dead?
Royal College of Physicans May 16 th 2017 Is Traditional Clinic Blood Pressure Dead? Professor Bryan Williams MD FRCP FAHA FESC Chair of Medicine UCL Director National Institute for Health Research Biomedical
More informationHypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital
Hypertension Update 2008 Warwick Jaffe Interventional Cardiologist Ascot Hospital Definition of Hypertension Continuous variable At some point the risk becomes high enough to justify treatment Treatment
More informationWhat s In the New Hypertension Guidelines?
American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the
More informationDEPARTMENT OF GENERAL MEDICINE WELCOMES
DEPARTMENT OF GENERAL MEDICINE WELCOMES 1 Dr.Mohamed Omar Shariff, 2 nd Year Post Graduate, Department of General Medicine. DR.B.R.Ambedkar Medical College & Hospital. 2 INTRODUCTION Leading cause of global
More informationVolume 6; Number 1 January 2012 NICE CLINICAL GUIDELINE 127: HYPERTENSION CLINICAL MANAGEMENT OF PRIMARY HYPERTENSION IN ADULTS (AUGUST 2011)
Volume 6; Number 1 January 2012 NICE CLINICAL GUIDELINE 127: HYPERTENSION CLINICAL MANAGEMENT OF PRIMARY HYPERTENSION IN ADULTS (AUGUST 2011) What s new in hypertension? NICE has issued an updated Clinical
More informationAn Epidemiological Overview
An Epidemiological Overview Cardiovascular disease (CVD) is the leading cause of death in the U.S. In 2005 CVD accounted for approximately 38 percent of all deaths CVD has been the number one killer in
More informationPrevention of Heart Failure: What s New with Hypertension
Prevention of Heart Failure: What s New with Hypertension Ali AlMasood Prince Sultan Cardiac Center Riyadh 3ed Saudi Heart Failure conference, Jeddah, 13 December 2014 Background 20-30% of Saudi adults
More information5.2 Key priorities for implementation
5.2 Key priorities for implementation From the full set of recommendations, the GDG selected ten key priorities for implementation. The criteria used for selecting these recommendations are listed in detail
More informationOnline Appendix (JACC )
Beta blockers in Heart Failure Collaborative Group Online Appendix (JACC013117-0413) Heart rate, heart rhythm and prognostic effect of beta-blockers in heart failure: individual-patient data meta-analysis
More information가정혈압의활용 CARDIOVASCULAR CENTER. Wook Bum Pyun M.D., Ph.D. HOME BLOOD PRESSURE MONITORING. Ewha Womans University, school of Medicine
가정혈압의활용 HOME BLOOD PRESSURE MONITORING CARDIOVASCULAR CENTER Wook Bum Pyun M.D., Ph.D. pwb423@ewha.ac.kr Ewha Womans University, school of Medicine Non-Invasive Blood Pressure Measurement 5-20% Resistant
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationDifficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair
Difficult-to-Control & Resistant Hypertension Anthony Viera, MD, MPH, FAHA Professor and Chair Objectives Define resistant hypertension Discuss evaluation strategy for patient with HTN that appears difficult
More informationHypertension Pharmacotherapy: A Practical Approach
Hypertension Pharmacotherapy: A Practical Approach Ronald Victor, MD Burns & Allen Chair in Cardiology Director, The Hypertension Center Associate Director, The Heart Institute Hypertension Center 1. 2.
More informationMPharmProgramme. Hypertension (HTN)
MPharmProgramme Hypertension (HTN) Slide 1 of 30 Overview Definition Prevalence Type Causes Diagnosis Management Patients perspective Slide 2 of 30 Definition It is not a disease! So what is it? What two
More informationDr Diana R Holdright. MD, FRCP, FESC, FACC, MBBS, DA, BSc. Consultant Cardiologist HYPERTENSION.
Dr Diana R Holdright MD, FRCP, FESC, FACC, MBBS, DA, BSc. Consultant Cardiologist HYPERTENSION www.drholdright.co.uk Blood pressure is the pressure exerted on the walls of the arteries when the heart pumps;
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationAmbulatory Blood Pressure Monitoring Clinical Practice Recommendations
Acta Medica Marisiensis 2016;62(3):350-355 DOI: 10.1515/amma-2016-0038 UPDATE Ambulatory Blood Pressure Monitoring Clinical Practice Recommendations Mako Katalin *, Ureche Corina, Jeremias Zsuzsanna University
More informationFirst line treatment of primary hypertension
First line treatment of primary hypertension Dr. Vijaya Musini Assistant Professor, Dept. Anesthesiology, Pharmacology and Therapeutics Manager, Drug Assessment Working Group Therapeutics Initiative Editor,
More informationCombination Therapy for Hypertension
Combination Therapy for Hypertension Se-Joong Rim, MD Cardiology Division, Yonsei University College of Medicine, Seoul, Korea Goals of Therapy Reduce CVD and renal morbidity and mortality. Treat to BP
More informationAssessing Blood Pressure for Clinical Research: Pearls & Pitfalls
Assessing Blood Pressure for Clinical Research: Pearls & Pitfalls Anthony J. Viera, MD, MPH, FAHA Department of Family Medicine Hypertension Research Program UNC School of Medicine Objectives Review limitations
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationCombination therapy Giuseppe M.C. Rosano, MD, PhD, MSc, FESC, FHFA St George s Hospitals NHS Trust University of London
Combination therapy Giuseppe M.C. Rosano, MD, PhD, MSc, FESC, FHFA St George s Hospitals NHS Trust University of London KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email:
More informationNew Hypertension Guideline Recommendations for Adults July 7, :45-9:30am
Advances in Cardiovascular Disease 30 th Annual Convention and Reunion UERM-CMAA, Inc. Annual Convention and Scientific Meeting July 5-8, 2018 New Hypertension Guideline Recommendations for Adults July
More informationPrimary hypertension in adults
Primary hypertension in adults NICE provided the content for this booklet which is independent of any company or product advertised Hypertension Welcome NICE published an updated guideline on the diagnosis
More informationHypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital
Hypertension and obesity Dr Wilson Sugut Moi teaching and referral hospital No conflict of interests to declare Obesity Definition: excessive weight that may impair health BMI Categories Underweight BMI
More informationAn Epidemiological Overview
An Epidemiological Overview Cardiovascular disease (CVD) is the leading cause of death in the U.S. In 2005 CVD accounted for approximately 38 percent of all deaths CVD has been the number one killer in
More informationRISE, FALL AND RESURRECTION OF RENAL DENERVATION. Michael A. Weber, MD State University of New York Downstate College of Medicine
RISE, FALL AND RESURRECTION OF RENAL DENERVATION Michael A. Weber, MD State University of New York Downstate College of Medicine Michael Weber, Disclosures Research/Trial Commitments and Consulting: Boston
More informationHypertension Management Controversies in the Elderly Patient
Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No
More informationHypertension mechanisms
הטיפול בלחץ דם בעזרת תרופות מישלב Hypertension mechanisms ESH Task Force Document. J Hypertens 2009 The history of development of antihypertensive drugs ESH Task Force Document. J Hypertens 2009 הטיפול
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationNew Antihypertensive Strategies to Improve Blood Pressure Control
New Antihypertensive Strategies to Improve Blood Pressure Control Antonio Coca, MD, PhD,, FRCP, FESC Hypertension and Vascular Risk Unit Department of Internal Medicine. Hospital Clínic (IDIBAPS) University
More informationHypertension and the Challenge of Adherence. Geneva Clark Briggs, Pharm.D., BCPS
Hypertension and the Challenge of Adherence Geneva Clark Briggs, Pharm.D., BCPS Outline Brief overview of HTN and pharmacologic therapies Role of pharmacists in collaboration with patients and physicians
More informationJared Moore, MD, FACP
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationInt. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences
Research Article JNC 8 versus JNC 7 Understanding the Evidences Anns Clara Joseph, Karthik MS, Sivasakthi R, Venkatanarayanan R, Sam Johnson Udaya Chander J* RVS College of Pharmaceutical Sciences, Coimbatore,
More informationhypertension Head of prevention and control of CVD disease office Ministry of heath
hypertension t. Samavat MD,Cadiologist,MPH Head of prevention and control of CVD disease office Ministry of heath RECOMMENDATIONS FOR HYPERTENSION DIAGNOSIS, ASSESSMENT, AND TREATMENT Definition of hypertension
More informationClinical guideline Published: 24 August 2011 nice.org.uk/guidance/cg127
Hypertension in adults: diagnosis and management Clinical guideline Published: 24 August 2011 nice.org.uk/guidance/cg127 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationMasked Hypertension. Why Should We Care? Dr. Peter J. Lin Director Primary Care Initiatives - Canadian Heart Research Centre
Masked Hypertension Why Should We Care? Dr. Peter J. Lin Director Primary Care Initiatives - Canadian Heart Research Centre PRESENTER DISCLOSURE Faculty: Dr. Peter Lin Relationships with commercial interests:
More informationNICE BHS Hypertension guidelines 2011 update
NICE BHS Hypertension guidelines 2011 update Review for clinicians Sept 2011 Mark Thomas West Midlands Hypertension Centre Heart of England NHS Trust www.wmhc.co.uk mark.thomas@heartofengland.nhs.uk Full
More informationState of the art treatment of hypertension: established and new drugs. Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland
State of the art treatment of hypertension: established and new drugs Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland First line therapies in hypertension ACE inhibitors AT
More informationHypertension and Cardiovascular Disease
Hypertension and Cardiovascular Disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,
More informationBlood Pressure Monitoring in Chronic Kidney Disease
Blood Pressure Monitoring in Chronic Kidney Disease Aldo J. Peixoto, MD FASN FASH Associate Professor of Medicine (Nephrology), YSM Associate Chief of Medicine, VACT Director of Hypertension, VACT American
More informationRationale for the use of Single Pill Combination. Yong Jin Kim, MD Seoul National University Hospital
Rationale for the use of Single Pill Combination Yong Jin Kim, MD Seoul National University Hospital Unmet Need of Hypertension Treatment Hypertension # 1 Risk Factor for Global Mortality 0 1 2 3 4 5 6
More informationObjectives. Describe results and implications of recent landmark hypertension trials
Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships
More informationBest Therapy for Resistant Hypertension: The PATHWAY-2 2 Study
Best Therapy for Resistant Hypertension: The PATHWAY-2 2 Study Antonio Coca MD, PhD, FRCP, FESC Council on Hypertension. European Society of Cardiology Hypertension and Vascular Risk Unit. Department of
More informationHigh-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension
(2005) 19, 491 496 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE High-dose monotherapy vs low-dose combination therapy of calcium channel blockers
More informationHypertension Update 2009
Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin
More informationAGING, BLOOD PRESSURE & CARDIOVASCULAR DISEASE EVENT RISK. Michael Smolensky, Ph.D. The University of Texas Austin & Houston
AGING, BLOOD PRESSURE & CARDIOVASCULAR DISEASE EVENT RISK Michael Smolensky, Ph.D. The University of Texas Austin & Houston Disclosures Partner: Circadian Ambulatory Diagnostics Consultant: Spot On Sciences
More informationUpdate on Current Trends in Hypertension Management
Friday General Session Update on Current Trends in Hypertension Management Shawna Nesbitt, MD Associate Dean, Minority Student Affairs Associate Professor, Department of Internal Medicine Office of Student
More informationEgyptian Hypertension Guidelines
Egyptian Hypertension Guidelines 2014 Egyptian Hypertension Guidelines Dalia R. ElRemissy, MD Lecturer of Cardiovascular Medicine Cairo University Why Egyptian Guidelines? Guidelines developed for rich
More informationTreatment of hypertension to achieve blood pressure control
Treatment of hypertension to achieve blood pressure control Item Type Report Authors Peter Mas-Mollinedo Publisher Irish Heart Foundation (IHF) Download date 01/11/2018 18:07:44 Link to Item http://hdl.handle.net/10147/310910
More informationLong-Term Care Updates
Long-Term Care Updates August 2015 By Darren Hein, PharmD Hypertension is a clinical condition in which the force of blood pushing on the arteries is higher than normal. This increases the risk for heart
More informationAppendix F: Clinical evidence tables
378 Appendix F: F.1 Blood pressure variability STUDY 1 P. M. Rothwell, S. C. Howard, E. Dolan, E. O'Brien, J. E. Dobson, B. Dahlof, N. R. Poulter, and P. S. Sever. Effects of beta blockers and calciumchannel
More informationHow clinically important are the results of the large trials in hypertension?
How clinically important are the results of the large trials in hypertension? Stéphane LAURENT, MD, PhD, FESC Pharmacology Department and PARCC / INSERM U970 Hôpital Européen Georges Pompidou, Université
More informationT. Suithichaiyakul Cardiomed Chula
T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial
More informationHow Low Do We Go? Update on Hypertension
How Low Do We Go? Update on Beth L. Abramson, MD, FRCPC, FACC As presented at the University of Toronto s Saturday at the University Session (September 2003) Arecent World Health Organization report states
More informationWhich antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017
Which antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017 The most important reason for treating hypertension in primary care is to prevent
More informationRESISTENT HYPERTENSION. Dr. Helmy Bakr Professor and Head of Cardiology Dept. Mansoura University
RESISTENT HYPERTENSION Dr. Helmy Bakr Professor and Head of Cardiology Dept. Mansoura University Resistant Hypertension Blood pressure remaining above goal in spite of concurrent use of 3 antihypertensive
More informationPatrick Kay, General and Interventional Cardiologist Auckland or healthpoint.co.nz
Patrick Kay, General and Interventional Cardiologist Auckland ipatkay@hotmail.com or healthpoint.co.nz Rotorua 2015 Rotorua 2015 Graphical example of true mean and variation, and of regression to the
More informationTodd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM
Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM Faculty Disclosure I have no financial interest to disclose No off-label use of medications will be discussed FIFTH ANNUAL SYMPOSIUM Recognize changes between
More informationDISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE
ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal
More informationImportance of Ambulatory Blood Pressure Monitoring in Adolescents
Importance of Ambulatory Blood Pressure Monitoring in Adolescents Josep Redon, MD, PhD, FAHA Internal Medicine Hospital Clinico Universitario de Valencia University of Valencia CIBERObn Instituto de Salud
More informationValsartan Amlodipine HCT Combination: Control To Goal. Dr. Sameh Shaheen M.B.B.Ch, MSc, MD, FESC, FSCAI. Prof of cardiology Ain Shams University
Valsartan Amlodipine HCT Combination: Control To Goal Dr. Sameh Shaheen M.B.B.Ch, MSc, MD, FESC, FSCAI Prof of cardiology Ain Shams University Sonesta Hotel Cairo Egypt December 4 th 5 th ; 213 Hypertension
More informationYounger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.
Appendix 2A - Guidance on Management of Hypertension Measurement of blood pressure All adults from 40 years should have blood pressure measured as part of opportunistic cardiovascular risk assessment.
More informationPre-ALLHAT Drug Use. Diuretics. ß-Blockers. ACE Inhibitors. CCBs. Year. % of Treated Patients on Medication. CCBs. Beta Blockers.
Pre- Drug Use % of Treated Patients on Medication 60 50 40 30 20 10 0 1978 Diuretics ß-Blockers ACE Inhibitors Year CCBs CCBs Beta Blockers Diuretics ACE Inhibitors 1980 1982 1984 1986 1988 1990 1992 IMS
More informationUpdate on HTN and ABPM. Raj Padwal Division of General Internal Medicine University of Alberta
Update on HTN and ABPM Raj Padwal Division of General Internal Medicine University of Alberta Disclosures Funding: CIHR, AIHS, HSF, UHF Research Collaboration: Novo Nordisk, CVRx Consulting: Vivus, Medtronic
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,
More informationTalking about blood pressure
Talking about blood pressure Mrs Khan 56 BP 158/99 BMI 32 Total cholesterol 5.4 (HDL 0.8) HbA1c 43 She has been promising to do more exercise and eat more healthily for the last 2 years but her weight
More informationModule 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension
Module 2 Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension 1 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
More informationRESISTANT HYPERTENSION
RESISTANT HYPERTENSION John D. Bisognano, MD PhD Professor of Medicine / Cardiology President-Elect, American Society of Hypertension Director, Outpatient Cardiology University of Rochester RESISTANT HYPERTENSION
More informationVA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005
VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,
More informationAmbulatory BP Monitoring: Getting the Diagnosis of Hypertension Right. Anthony J. Viera, MD, MPH, FAHA Professor and Chair
Ambulatory BP Monitoring: Getting the Diagnosis of Hypertension Right Anthony J. Viera, MD, MPH, FAHA Professor and Chair Objectives Review limitations of office BP in making a correct diagnosis of hypertension
More informationIndividual management of arterial hypertension. Doumas Michael, Internist Lecturer, Aristotle University, Thessaloniki
Individual management of arterial hypertension Doumas Michael, Internist Lecturer, Aristotle University, Thessaloniki From Population to Individual Management of Arterial Hypertension Epidemiologic impact
More informationImprovement of drug adherence using single pill combinations:
Improvement of drug adherence using single pill combinations: what is the evidence? Prof. Michel Burnier Service of Nephrology and Hypertension, CHUV, Lausanne, Switzerland Potentialcauses of non-adherence
More informationManagement of Hypertension in special groups. DR-Mohammed Salah Assistant Lecturer of Cardiology Mansoura University
Management of Hypertension in special groups BY DR-Mohammed Salah Assistant Lecturer of Cardiology Mansoura University AGENDA SPECIAL GROUPS SPECIFIC DRUDS FOR SPECIAL GROUPS TARGET BP FOR SPECIAL GROUPS:
More informationHypertension and the 2017 Guidelines Meeting the Targets in Small Groups. Lisa Ivy APRN
Hypertension and the 2017 Guidelines Meeting the Targets in Small Groups Lisa Ivy APRN The 2017 Guideline is an Update to JNC7 New information regarding BP related risk of CVD Ambulatory BP monitoring
More informationHypertension: JNC-7. Southern California University of Health Sciences Physician Assistant Program
Hypertension: JNC-7 Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! Reference Card
More informationRationale for the use of Single Pill Combination (SPC) and Asian data of ARB/CCB SPC
Rationale for the use of Single Pill Combination (SPC) and Asian data of ARB/CCB SPC Seung Woo Park, MD Samsung Medical Center BP Control Rates in Asia BP controlled BP uncontrolled 24.3% 36.6% 19% Turkey
More informationIncidental Findings; Management of patients presenting with high BP. Phil Swales
Incidental Findings; Management of patients presenting with high BP Phil Swales Consultant Physician Acute & General Medicine University Hospitals of Leicester NHS Trust Objectives The approach to an incidental
More informationUnderstanding the importance of blood pressure control An overview of new guidelines: How do they impact daily current management?
Understanding the importance of blood pressure control An overview of new guidelines: How do they impact daily current management? Slides presented during CDMC in Almaty, Kazakhstan on Saturday April 12,
More informationUse and Interpretation of Home Blood Pressure Monitoring
Use and Interpretation of Home Blood Pressure Monitoring BLOOD PRESSURE in year 2015 PARAMETERS TODAY Gianfranco Parati University of Milano-Bicocca & Ospedale S.Luca, IRCCS, Istituto Auxologico Italiano
More informationEvolving Concepts on Hypertension: Implications of Three Guidelines (JNC 8 Panel, ESH/ESC, NICE/BSH)
Evolving Concepts on Hypertension: Implications of Three Guidelines (JNC 8 Panel, ESH/ESC, NICE/BSH) Sidney C. Smith, Jr. MD, FACC, FAHA, FESC Professor of Medicine/Cardiology University of North Carolina
More informationUpdate in Hypertension
Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded
More informationClinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital
Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8 Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Objectives Review the Eighth Joint National Committee (JNC
More informationHypertension Clinical case scenarios for primary care
Hypertension Clinical case scenarios for primary care Implementing NICE guidance August 2011 NICE clinical guideline 127 What this presentation covers Five clinical case scenarios, including: presentation
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%
More informationHTN talk_l Davis_ /28/2018
1 2 GUIDELINES PUBLISHED AHEAD OF PRINT NOV 13, 2017 = SAME DAY AS PUBLIC PRESENTATION LESLIE L DAVIS, PHD, RN, ANP-BC, FPCNA, FAANP, FAHA The New Guidelines Have Been Published! Whelton PK, Carey RM,
More informationHypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town
Hypertension targets: sorting out the confusion Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Historical Perspective The most famous casualty of this approach was the
More informationThe Road to Renin System Optimization: Renin Inhibitor
The Road to Renin System Optimization: Renin Inhibitor A New Perspective on the Renin-Angiotensin System (RAS) Yong-Jin Kim, MD Seoul National University Hospital Human and Economic Costs of Hypertension
More informationΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH
ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH Hypertension Co-Morbidities HTN Commonly Clusters with Other Risk
More informationESSENTIAL HYPERTENSION
E S S E N T I A L H Y P E R T E N S I O N Elevated blood pressure is one of the most important causes of cardiovascular disease. J A Ker MB ChB, MMed, MD Professor and Deputy Dean Faculty of Health Sciences
More informationHypertension Management Focus on new RAAS blocker. Disclosure
Hypertension Management Focus on new RAAS blocker Rameshkumar Raman M.D Endocrine Associates of The Quad Cities Disclosure Speaker bureau Abbott, Eli Lilly, Novo Nordisk, Novartis, Takeda, Merck, Solvay
More informationEFFICACY & SAFETY OF ORAL TRIPLE DRUG COMBINATION OF TELMISARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE IN THE MANAGEMENT OF NON-DIABETIC HYPERTENSION
EFFICACY & SAFETY OF ORAL TRIPLE DRUG COMBINATION OF TELMISARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE IN THE MANAGEMENT OF NON-DIABETIC HYPERTENSION Khemchandani D. 1 and * Arif A. Faruqui 2 1 Bairagarh,
More informationUsing the New Hypertension Guidelines
Using the New Hypertension Guidelines Kamal Henderson, MD Department of Cardiology, Preventive Medicine, University of North Carolina School of Medicine Kotchen TA. Historical trends and milestones in
More informationBy Prof. Khaled El-Rabat
What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating
More informationBrent M. Egan, MD Professor of Medicine USCSOM Greenville
Contemporary Management of Uncontrolled and Treatment Resistant Hypertension Brent M. Egan, MD Professor of Medicine USCSOM Greenville Disclosures (past 3 years): Honoraria: BCBSSC, Medtronic Grant Support:
More informationHypertension Putting the Guidelines into Practice
Hypertension 2017 Putting the Guidelines into Practice Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or
More information